Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria

Alan Brennan(University of Sheffield), Doreen McBride(University College London), Ion Agirrezabal(University of California, San Francisco), S.T. Alexopoulos(Novartis (United Kingdom)), Anna Halliday(Novartis (United Kingdom)), Maria‐Magdalena Balp(Novartis (Switzerland)), Donald E. Stull(IQVIA (United States)), Torsten Zuberbier(Humboldt-Universität zu Berlin), Matthew Griffiths(Costello Medical Consulting (United Kingdom))
PharmacoEconomics
May 21, 2016
10.1007/s40273-016-0412-1
Cited by 40

Related Papers

Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
|Journal of Allergy and Clinical Immunology|2010|1.8k
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.5k
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
|Allergy|2021|1.2k
The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Allergy|2014|1.2k
Chronic rhinosinusitis in Europe - an underestimated disease. A GA2LEN study
|Allergy|2011|1.1k